Impax Laboratories Inc

Impax Laboratories — Q2 2015 Earnings Presentation

22 slides from Impax Laboratories's earnings presentation, Aug 10, 2015

  1. Slide 1: Second Quarter 2015 Results

    Impax Second Quarter 2015 Results August 10, 2015

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    Impax Cautionary Statement Regarding Forward Looking Statements To the extent any statements made in this presentation contain information that is not historical these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on curren

  3. Slide 3: Agenda

    Agenda mem 42 2015 Highlights and Subsequent Events ame Update on Four Key Areas of Focus mae ©6201) Guidance ee OCA ee ©2 2015 Financial Results

  4. Slide 4: Highlights & Update

    Highlights & Update Fred Wilkinson President & Chief Executive Officer

  5. Slide 5: Q2 2015 Highlights and Subsequent Events

    Q2 2015 Highlights and Subsequent Events Q2 2015 results Revenue growth of approximately 14% Tower’ acquisition enhanced Brand and Generic portfolio Launched six generic products Strong early performance from RYTARY® Specialty Pharma (Brand) business profitable « Achieving Tower acquisition strategi

  6. Slide 6: 1. Focusing on Quality

    1. Focusing on Quality Hayward « Submitted response to Form 483 on June 1 All commitments have been completed and submitted Inspection has been officially closed No formal update on status of the closure of the Warning Letter or PAI’s on multiple products Continued dialogue with agency regarding our

  7. Slide 7: 2. Maximizing Generic Platform

    2. Maximizing Generic Platform Year to Date Potential Generic Market Update on Product Launches Launches in 2015 Products Lamotrigine ODT — FTF Azelastine Nasal Olopatadine Nasal Oxymorphone IR tablet Metaxalone 400mg IR tablet Fenofibrate 120mg tablets Cyproheptadine IR tablet Current U.S. Brand/Ge

  8. Slide 8: 2. Maximizing Specialty Pharma Platform

    2. Maximizing Specialty Pharma Platform (Coritopa ond eidopa) tended Rese Coos Over 21,000 scripts since launch 14% TRx growth prior 4 weeks + Strong product interest results in enhanced physician office access + Driving awareness and adoption > 83% of commercial Rx’s approved by payers > 76% of Med

  9. Slide 9: 3. Optimizing R&D

    3. Optimizing R&D Ss ANDA Pipeline Current U.S. Brand/Generic Market Sales - $19B Pending at FDA - $98 27% Confirmed/Potential Under Development - $108 45% Potential FTF or FTM FTF or FTM 25 10 10 F a Bo Internal External Internal External [Other SOD MControled-Release SOD [ll Alternative Dosage For

  10. Slide 10: 4. Business Development Acceleration

    4. Business Development Acceleration Announced divestiture of Daraprim® for $55 million in cash » Non-core asset acquired as part of Tower acquisition » Returns approximately 8% of $700 million acquisition price Integration of Tower acquisition essentially complete » Focusing on achieving strategic

  11. Slide 11: Financial Review

    Financial Review Bryan Reasons Senior Vice President & Chief Financial Officer

  12. Slide 12: Q2 2015 Financial Summary

    Q2 2015 Financial Summary Total Net Revenues $214.2 $143.1 49.7% $188.1 13.9% Adjusted Gross Profit $1071 $678 58.0% $1212 (11.7%) Adjusted Gross Margin 50.0% 47.4% — 2.6ppts 64.4% (14.4ppts) Adjusted Research & Development Expense $17.0 $150 13.3% $21.3 (20.0%) Adjusted Selling, General & Administr

  13. Slide 13: Q2 2015 Generic and Specialty Pharma Summary

    Q2 2015 Generic and Specialty Pharma Summary GENERIC DIVISION Total Net Revenues $1747 $1287 35.7% $176.4 (1.0%) Adjusted Gross Profit $752 $579 29.9% $117.2 (35.8%) Adjusted Gross Margin 431% 45.0% — (1.9ppts) 66.5% (23.4ppts) Adjusted Operating Income $537 $420 27.9% $100.1 (46.4%) SPECIALTY PHARM

  14. Slide 14: Improved Capital Structure

    Improved Capital Structure Term Loan Termination Benefits Prior Credit Facility + $435 secured term loan + 4.5% + 1% LIBOR floor + Minimum annual interest of approximately $24 million + Restrictive covenants * $600 million unsecured convertible * 2% coupon + Adjusted annual interest of $12 million N

  15. Slide 15: Full-year 2015 Financial Guidance Update

    Full-year 2015 Financial Guidance Update $ millions | Prior Updated Adjusted Gross Margin* Mid 50% range Low 50% range Adjusted Research & Development Expense* $80 to $85 $75 to $80 Adjusted Selling, General & Administrative Expense $170 to $180 $170 to $180 Adjusted Interest Expense** Not provided

  16. Slide 16: Key Priorities

    Key Priorities

  17. Slide 17: Q&A

  18. Slide 18: Appendix

    Appendix

  19. Slide 19: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations The following table reconciles reported net (loss) income to adjusted net income (Unaudited, amounts in thousands, except per share and per share data) June 30, 2015 Net (oss) income S$ (4852) Adjusted to add (deduct): Amortization ® 162 Hayward facility remediation

  20. Slide 20: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations The following table reconciles total Company reported cost of revenues, research and development expenses, and selling, general and administrative expenses to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development e

  21. Slide 21: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations The following table reconciles reported net (loss) income to adjusted EBITDA. The following table reconciles reported interest expense to adjusted (Unaudited, amounts in thousands) interest expense (Unaudited, amounts in thousands) Three months ended Three months end

  22. Slide 22: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations The following tables reconcile the Impax Generics and Impax Specialty Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousands) Generic Divisi

Impax Laboratories — Q2 2015 Earnings Presentation on 6ix